MétaCan
Menu
Back to cohort
Record W4399926559 · doi:10.1016/j.esmoop.2024.103538

38MO Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial

2024· article· en· W4399926559 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.

Bibliographic record

VenueESMO Open · 2024
Typearticle
Languageen
FieldMedicine
TopicEndometrial and Cervical Cancer Treatments
Canadian institutionsUniversity of CalgaryMcGill University Health Centre
Fundersnot available
KeywordsEndometrial cancerOncologyInternal medicineProgression-free survivalMedicineOverall survivalCancerDNA mismatch repairGynecology

Abstract

fetched live from OpenAlex

In Part 1 of the phase 3 RUBY trial (NCT03981796) in pA/rEC, patients (pts) receiving dostarlimab (dostar)/carboplatin-paclitaxel (CP) exhibited significant benefits in PFS and overall survival versus CP alone. Outcomes may be further improved by adding a poly(ADP-ribose) polymerase inhibitor (PARPi). Here we report results from Part 2 of RUBY of dostar/CP followed by dostar/niraparib (nira; a PARPi) maintenance therapy in pts with pA/rEC. Pts were randomized 2:1 to dostar 500 mg IV + CP Q3W for 6 cycles followed by dostar 1000 mg IV Q6W + nira (individualized starting dose of 200 or 300 mg) PO daily for ≤3 years from randomization or to placebo (PBO) + CP Q3W for 6 cycles followed by PBOs for ≤3 years. The primary endpoint was PFS in the overall and MMRp/MSS populations. 291 pts were randomized (192 dostar/CP + dostar/nira; 99 PBO/CP). PFS was significantly improved in pts receiving dostar/CP + dostar/nira vs PBO/CP in the overall and MMRp/MSS populations (Table). In pts with endometrioid carcinoma, pts with other histologies, and across most biomarker subgroups (eg, TP53mut), the hazard ratio (HR) directionally favored dostar/CP + dostar/nira in the overall and MMRp/MSS populations. The safety profile observed was consistent with those of the individual agents.Table: 38MOPFSDostar/CP+dostar/niraPBO/CP+PBOHR (95% CI)Overall, n192990.60 (0.43–0.82) P=0.0007Median (95% CI), mo14.5 (11.8–17.4)8.3 (7.6–9.8)-MMRp/MSS, n142740.63 (0.44–0.91) P=0.0060Median (95% CI), mo14.3 (9.7–16.9)8.3 (7.6-9.8)-Pre-specified exploratory analysesNo. of pts with events/No. of ptsAll pts95/19269/99-Endometrioid carcinoma52/11446/670.58 (0.39–0.87)Other histologies42/7623/320.53 (0.32–0.88)Molecular subgroupbPOLεmut0/31/2-adMMR/MSI-H12/3710/170.45 (0.20–1.05)TP53mut27/3910/100.29 (0.13–0.63)No specific molecular profile37/7531/460.61 (0.38–0.99)Not evaluable19/3817/240.71 (0.37–1.37)a<20 events. bBased on whole exome sequencing. Open table in a new tab a<20 events. bBased on whole exome sequencing. RUBY Part 2 met its primary endpoint and is the first study to show significant and clinically meaningful improvement in PFS in the MMRp/MSS and overall populations. The trial is ongoing for OS follow-up. The safety profile observed was generally consistent with the known safety profiles of the individual agents. These data demonstrate a potential role for PARPi maintenance in pts receiving dostar/CP, especially for MMRp/MSS tumors.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.492
Threshold uncertainty score0.834

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.073
GPT teacher head0.368
Teacher spread0.295 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it